Beijing Jiade's profits soar in the first half of 2022, with sales growth exceeding 30%

Firstly, I would like to express my gratitude to all universities, enterprises, and institutions for their full trust and strong support towards Beijing Jiade

• Preliminary data shows that,2022年上半年： Order volume growth60%Sales revenue growth50%Growth in the number of employees20%

• 2022Performance Outlook for the Second Half of the Year: Expected Growth in Sales Revenue20%-30%And continue to maintain high profitability

• 2025Mid year goal: Management confirms sales revenue target of5Billion yuan and increase the profit target to50%Left and right, set sustainable development goals to continuously improve human health

We have successfully provided support for demanding customer projects in the fields of biopharmaceuticals, vaccine development, university laboratories, and scientific research,

Our laboratory products, which focus on providing equipment and technology for life science research and pharmaceutical laboratories, have achieved strong growth.

This growth is due to economies of scale, a favorable product portfolio, and the recognition of deferred costs by each customer.

Beijing Jiade is expected to2022Strong growth is expected in the second half of the year. We are very optimistic about the future development of our business because we are moving forward at full speed,